Actavis to Quit China as Trouble Seen for Little Profit

Actavis Plc, the second-biggest generic drugmaker by market capitalization, said it will end its presence in China because of the difficult business climate.

While the country has more than 1.3 billion potential customers, the government has made it a difficult place to conduct business, Actavis Chief Executive Officer Paul Bisaro said in an interview. The company has sold one operation there and is in talks to sell another.